Mark Your Calendars: Kiora Pharmaceuticals Reschedules Special Stockholders Meeting to September 27th!

“Kiora Pharmaceuticals: Shaping the Future with Your Vote – Special Meeting Rescheduled to September 27!”

Encinitas, California – September 1, 2023 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), affectionately known as “Kiora,” is in the midst of an important journey, and your voice is crucial to the destination. Here’s the scoop:

On August 31, 2023, Kiora hosted a Special Meeting of Stockholders at 9:00 a.m. Pacific Time, all fired up and ready to make impactful decisions. But sometimes, the stars don’t align as expected. The meeting was adjourned, and not a single order of business was conducted. Why? We missed the magic number – the quorum, representing one-third of the voting power of outstanding shares.

So, what’s the plan now? Drumroll, please! We’re reconvening at 8:30 a.m. Pacific Time on Wednesday, September 27, 2023, right at the heart of Kiora, 332 Encinitas Blvd., Suite 102, Encinitas, CA 92024. This gives our valued stockholders more time to cast their votes on the proposals outlined in our definitive proxy statement, filed with the United States Securities and Exchange Commission (the “SEC”) on July 21, 2023.

During this adjournment, we’re on a mission – to rally your support and secure the necessary votes. We’ve brought in the cavalry, in the form of Alliance Advisors, a seasoned proxy solicitor, to help us cross the finish line.

So far, proxies have been submitted by stockholders representing around 23% of our outstanding common stock. Those who’ve already cast their votes, you’re in! No need to redo it.

But here’s the call to action: To all stockholders of record as of July 18, 2023, who haven’t cast their votes yet – we’re counting on you! September 26, 2023, at 11:59 p.m. (Eastern Time) is the deadline. We’ve made it easy; just reach out to Alliance Advisors at 200 Broadacres Drive, 3rd Fl., Bloomfield, NJ 07003, Telephone: Toll-Free: 1-888-596-1905 and Outside North America: 1-973-873-7700 or Email: [email protected] if you need assistance or have questions.

Here’s the deal: If we don’t get the quorum we need at the adjourned Special Meeting, we might have to do it all over again. And, well, that comes with additional costs. Let’s make every vote count, and together, we’ll shape Kiora Pharmaceuticals’ future.

About Kiora Pharmaceuticals

At Kiora Pharmaceuticals, we’re on a mission that’s nothing short of extraordinary. Picture this: a clinical-stage biotechnology company, driven by a burning passion to change lives, one breakthrough at a time.

Our star player? Meet KIO-301, our molecular photoswitch with the power to rekindle hope in the hearts of those battling orphan retinal diseases like Retinitis Pigmentosa. But that’s not all – we’re not stopping there. The same miracle-worker, KIO-301, is set to dazzle in the fight against Choroideremia and Stargardt’s Disease. It’s not just a product; it’s a beacon of light for those facing inherited and age-related retinal degeneration.

But wait, there’s more! Enter KIO-104, our next-gen champion, designed to take on posterior non-infectious uveitis. It’s not just non-steroidal; it’s a game-changer in immune modulation. With picomolar potency and a rock-solid track record in blocking T cell proliferation and taming proinflammatory cytokines, KIO-104 isn’t just good – it’s best-in-class.

Join us on this thrilling journey as we rewrite the narrative of medical possibilities. At Kiora, we’re not just developing products; we’re crafting hope, one molecule at a time.

Forward-Looking Statements

In our quest for innovation, we’re setting sail towards uncharted waters, but we want you to know we’ve got a map. You see, some of the statements in this press release are more than just words; they’re glimpses into the future, guided by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

We’re not just dreaming; we’re talking about the development and commercialization of our remarkable products like KIO-301 and KIO-104. These aren’t just projects; they’re promises we’re determined to fulfill. But, and it’s a big ‘but,’ success and approvals aren’t guaranteed. We’re aware of the challenges and the ever-ticking clock.

In our journey, we face risks and uncertainties, the kind that can make or break dreams. The ability to conduct clinical trials on time, secure regulatory approvals, and navigate the ever-shifting market conditions – these are the battles we must win. And don’t forget the hidden factors we might not even be aware of yet.

But here’s the thing – we’re not here to shy away from challenges. We’re pioneers, and we’re up for the adventure. The forward-looking statements in this press release are our way of sharing our vision, our compass for the future. But remember, these statements are like snapshots in time, and we’re not bound by them. We’re committed to transparency, and if things change, we’ll let you know. Our promise is to keep pushing the boundaries, striving for progress, and always staying true to our mission, no matter where the journey takes us.

Leave a Comment